Temporary scans during prostate cancer treatment can help guide treatment

new prostate cancer study suggests that adding temporary scans during treatment can help guide patients' treatment. After two rounds of l-177 (177Lu)-PSMA radiological ligand therapy, metastatic degenerative antigen (PSMA) electron emission fault scanning (PET) imaging showed significant predictive value for patient survival. The study was published at the 2019 annual meeting of the Society for Nuclear Medicine and Molecular Imaging (SNMMI).
According to the U.S. National Cancer Institute, the current five-year survival rate for patients with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is critical to providing optimal care.
In Phase 2 clinical trials, 177 Lu-PSMA treatments showed promising results in treating patients with metastatic desopathic prostate cancer. The treatment usually involves a preliminary PSMA PET scan to identify patients who are eligible for treatment. Although temporary PET scans are highly predictable for patients with lymphoma, previous concepts have not been explored in prostate cancer patients treated with 177Lu-PSMA.
The researchers conducted a retrospective analysis of patients who under undergoed a baseline scan of the 177Lu-PSMA RLT after two 177Lu-PSMA RLT cycles at the Klinikum rechts der Isar Hospital at the Technical University of Munich, Germany.
The researchers used qPSMA, an in-house developed software, to assess tumor loads throughout the body, rather than standard ingestions, a common parameter in this analysis. "We used three classification methods to evaluate tumor responses using changes in PSMA-avid tumor volume from baseline to second PSMA PET," explains Andrei Gafita, M.D., "and then we found that tumor responses assessed for temporary PSMA PET after two RLT cycles were associated with overall survival." "
that temporary PSMA PET can be used to evaluate treatment response in patients receiving 177Lu-PSMA RLT," said Gifita, a professor at the University of New York. In addition, the occurrence of new lesions in PSMA PET is a prognostic factor for disease progression and can be included in tumor responses defined based on PSMA PET imaging. " further analysis of clinical parameters is necessary," Gafita added, "and this analysis paves the way for the use of temporary PSMA PET in a forward-looking environment during the treatment of 177Lu-PSMA radioactive matings." " (Compiled by this web)